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Introduction
Growth hormone deficiency (GHD) is usually sporadic
and may be a result of environmental cerebral insults or
developmental anomalies. However, 3-30% of growth 
hormone (GH) deficient cases have an affected first-degree
relative, suggesting a genetic etiology (1). Familial isolated
growth hormone deficiency (IGHD) can result from genetic
defects in genes encoding the GH, the GH secretagogue
receptor, or the GH-releasing hormone receptor (GHRHR). It
has been estimated that the mutations in the human
GHRHR gene cause approximately 10% of autosomal 
recessive familial IGHD cases (2). 
Patients with GHRHR mutations have marked dwarfism
transmitted in a recessive fashion, and are phenotypically
and biochemically indistinguishable from other forms of
IGHD. 
Regardless of etiology, early GH therapy in GHD children
aims to prevent neonatal hypoglycemia and contribute to the
attainment of better adult height. Age at initiation of GH 
treatment is one of the variables that influence final height (3). 
We present here two siblings with clinical findings of
IGHD due to a nonsense mutation in the GHRHR gene who
responded well to GH therapy despite late admission. 
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mutations exhibit pronounced dwarfism and are phenotypically and 
biochemically indistinguishable from other forms of isolated growth hormone
deficiency (IGHD). We presented here two siblings with clinical findings of
IGHD due to a nonsense mutation in the GHRHR gene who reached their 
target height in spite of late GH treatment. Two female siblings were 
admitted to our clinic with severe short stature at the age of 13.8 (patient 1)
and 14.8 years (patient 2). On admission, height in patient 1 was 107 cm (-8.6
SD) and 117 cm (-6.7 SD) in patient 2. Bone age was delayed in both patients
(6 years and 9 years). Clinical and biochemical analyses revealed a diagnosis
of complete IGHD (peak GH levels on stimulation test was 0.06 ng/mL in
patient 1 and 0.16 ng/mL in patient 2). Patients were given recombinant
human GH treatment. Genetic analysis of the GH and GHRHR genes revealed
that both patientscarried the GHRHR gene mutation p.Glu72X (c.214 G>T) in
exon 3 in homozygous (or hemizygous) state. After seven years of GH 
treatment, the patients reached a final height appropriate for their target
height. Final height was 151 cm (-1.5 SD) in patient 1 and 153 cm (-1.2 SD) in
patient 2. In conclusion, genetic analysis is indicated in IGHD patients with
severe growth failure and a positive family history. In spite of the very late
diagnosis inthese two patients who presented with severe growth deficit due
to homozygous loss-of-function mutations in GHRHR, their final heights
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Two female siblings were admitted to our clinic with
severe short stature at the age of 13.8 (patient 1) and 14.8
years (patient 2) (Figure 1). On admission, patient 1 
measured 107 cm (-8.6 SD) in height, and patient 2 117 cm
(-6.74 SD). Bone age was delayed in both patients 
(corresponding to ages 6 years and 9 years at 13.8 and 14.8
years, respectively). Birth weight was 3000 g in patient 
1 and 3200 g in patient 2. No history of neonatal 
hypoglycemia was reported. Their target height was 153
cm (-1.18 SD). Their parentally adjusted height deficits were
-7.42 SD and -5.56 SD respectively.
Clinical examination revealed minimal midfacial 
hypoplasia with frontal bossing, depressed nasal bridge,
abdominal obesity, high-pitched voice, and depressive
behavior in addition to severe short stature (Figure 2). Both
children were prepubertal and their level of intelligence
appeared to be normal. Biochemichal analysis revealed very
low levels of insulin-like growth factor-1 (IGF-1) and 
IGF-binding protein-3 (IGFBP-3), dyslipidemia, low basal
GH, normal thyroid function tests, and normal levels of 
cortisol, adrenocorticotropic hormone (ACTH) and prolactin
(Table 1). Insulin-induced hypoglycemia and L-Dopa 
stimulation tests were applied to the patients as GH 
stimulation tests. GH levels in response to stimulation tests
were very low and set the diagnosis of severe complete
IGHD in both patients.  
Magnetic resonance imaging (MRI) showed anterior
pituitary hypoplasia in both sisters. Treatment was initiated
with recombinant human GH (rhGH) in a dose of 
0.2 mg/kg/week administered as a daily subcutaneous
injection. Chronological age was 13.9 years in patient 1
and 14.8 years-in patient 2. 
During follow-up, onset of puberty was noted at 15.6
years in patient 1 and at 15.3 years in patient 2. Bone ages
were 8 years 10 months in both patients at pubertal onset.
Patient 2 received gonadotropin-releasing hormone analog
(GnRHa) therapy in order to delay puberty and extend the
beneficial effect of GH treatment on height gain. However,
after one year of GnRHa treatment, no pubertal or bone age
arrest was observed (bone age increased from 8 years 10
months to 12 years in one year), and GnRHa therapy 
was stopped. Menarche occurred at age 18.16 years 
in patient 1 and at 19.5 years in patient 2. Maternal 
menarcheal age was not precise. After seven years of GH
treatment, patients reached their target height. 
Final height was 151 cm (-1.52 SD) in patient 1 and 153 cm
(-1.18 SD) in patient 2 (Figure 2). 
Genetic investigation included analysis of the GH and
GHRHR genes, which revealed that both patients carry a
GHRHR gene mutation p.Glu72X (c.214 G>T) in exon 3 in
homozygous (or hemizygous) state. 
Discussion 
Familial IGHD is associated with at least four distinct
forms  (4). Two forms show autosomal recessive 
inheritance (IGHD type 1A and 1B), one form has autosomal
dominant inheritance (IGHD type 2), and one is X-linked
(IGHD type 3). Type 1B is the most frequently encountered
form and could result from genetic defects in either 
GH gene or GHRHR gene (5). The GHRHR gene encodes a
423-aminoacid receptor protein and is essential for 
GHRH-stimulated secretion of GH (6).
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Figure 1. a) Growth chart of patient 1;    target height final height Figure 1. b) Growth chart of patient 2;      target height final height
Female
Name:
Surname:       B.Ç
Date of birth: 1989
Date of examination:
Age:
Female
Name:
Surname:       Z.Ç
Date of birth:  1988
Date of examination:
Age:
Height Height
0-6 year* 0-6 year*
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1 15 53 3   c cm m 1 15 53 3   c cm m
1 15 51 1   c cm m   GHRHR gene defects are recognized as the cause of
approximately 10% of autosomal recessive IGHD cases (2). 
GHRHR mutations reported to date include six 
splice site mutations, two microdeletions, two nonsense
mutations, seven missense mutations, and one in the 
promoter gene (7,8,9,10). Our patients carried the GHRHR
gene nonsense mutation p.Glu72X (c.214 G>T) in exon 3.
Most cases with this same mutation originated from Asia,
especially from India or Sri Lanka (11,12).
Characteristics of patients with GHRHR mutations 
are very similar to those with GH gene defects. Patients
carrying  GHRHR mutations usually have high-pitched 
voices, increased abdominal fat, very short but normally
proportioned stature, normal intelligence, minimal facial
hypoplasia, very low levels of GH and IGF-1, and anterior
pituitary hypoplasia on MRI (13,14). Fertility is usually not
affected, but puberty is reported to be delayed, especially in
male patients (15). The female patients described herein
showed similar characteristics of severe GHD. 
Both patients had anterior pituitary hypoplasia on MRI.
Mutations in GHRHR are usually associated with anterior
pituitary hypoplasia but normally placed posterior pituitary
on MRI. Given the important role of GHRH in regulating 
the proliferation and function of somatotroph cells, 
abnormalities in the GHRHR has been expected to cause
anterior pituitary hypoplasia (13). 
The aim of GH treatment is to avoid neonatal 
hypoglycemia and to attain better adult height. Our patients
had no history of neonatal hypoglycemia. Late admission 
of patients with severe growth retardation is one important
factor that compromises height increment. Early recognition
of GHD is essential for an optimal height outcome (16). At
admission, our patients were very short and their 
ages were not very young. It is known that final height is
correlated with height for chronological age at diagnosis (3)
the higher the chronological age, the lower the final height
reached by the patients.  One important factor in evaluating
response to GH therapy is extent of attainment of the
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Figure 2. a) Two sister with GH-releasing hormone receptor (GHRHR)
gene mutation: before treatment
Figure 2. b) Patients with GH-releasing hormone receptor (GHRHR)
mutation: after treatment
Table 1. Biochemical analysis of patients on admission
Patient 1 Patient 2
Basal GH (ng/mL) 0.1 0.0
Peak GH after insulin-induced  0.1 0.0
hypoglycemia (ng/mL) (n>10)
Peak GH after L-DOPA test (ng/mL) (N>10 ) 0.1 0.2
Basal IGF-1 (ng/mL) 7.5 (-4.8 SD) 4.2 (-5.3 SD)
Basal IGFBP-3 (ng/mL) 626 (-6.1 SD) 612 (-6.3 SD)
fT4 (pmol/L) (N: 11-22) 15.6    21.6
TSH (mIU/mL) (N: 0.5-5) 4.2 3.1
Cortisol (mcg/dl) (N: 5-23) 23.3 21.1
ACTH (pg/mL) (N:5-50) 33.5  27.5
Basal LH (mIU/mL)  0.2  0.2
Stimulated LH (mIU/mL)  2.6 6.8
Prolactin (ng/mL) (N:3.4-24) 26.9 35.6
Total cholesterol (mg/dL) (N:<200) 233 218
HDL-C (mg/dL) (N: >40) 45 52
LDL-C (mg/dL) (N: <100) 157 139 
VLDL-C (mg/dl) (N:<30) 31 27
Triglycerides (mg/dL) (N<130) 153 136
GH: growth hormone;  IGF-1: insulin like growth factor-1;  IGFBP-3: 
IGF binding protein-3; ACTH: adrenocorticotropic hormone; LH: Luteinizing hormone;
FSH: follicle stimulating hormonepatient’s genetic targeted height. Our patients achieved
their target height despite the very late age at diagnosis. In
addition to age at diagnosis, compliance to GH therapy, late
onset of puberty and slow pubertal  maturation may be
important factors in attainment of a satisfactory final height.
Patient 1 entered puberty at age of 15.6 years and patient
2 - at 15.3 years. The duration of puberty was also normal,
being 2.6 years in patient 1 and 4.3 years in patient 2.
however use of GnRHa in patient 2 might have modified
the duration of puberty.  In addition, the severe degree of
GHD in our patients may have affected the height gain. It is
well known that growth rates correlate inversely with peak
GH levels. The more severe the GH deficit is, the better the
growth response is to GH (17). 
In conclusion, genetic defects in related genes should
be suspected in IGHD patients with severe growth failure
and a positive family history, and molecular studies are 
indicated in such patients. In spite of the very late 
admission of these patients with severe growth deficit due
to GHRHR gene mutations, their final heights reached the
parentally adjusted height, probably because of delayed
puberty. This observation indicates that prolonged GH
replacement in patients with severe GHD will be beneficial,
even when the diagnosis is made at older ages.
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